Business Wire

Lattice Continues Rapid Product Portfolio Expansion Enabling the Next Era of Innovation

5.12.2023 18:20:00 CET | Business Wire | Press Release

Share

Today at the Lattice Developers Conference, Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, continued its rapid product portfolio expansion with the launch of multiple new hardware and software solutions. Lattice introduced two new innovative mid-range FPGA device families built on the award-winning mid-range Lattice Avant™ platform – Lattice Avant™-G and Lattice Avant™-X, designed for general purpose and advanced connectivity, respectively. Lattice announced new versions of its application-specific solution stacks for artificial intelligence (AI), embedded vision, security, and factory automation, each of which are expanded with new features and capabilities to help accelerate customer time-to-market. Lattice released updated versions of its software tools and Glance by Mirametrix® computer vision software.

“At Lattice, we’re focused on enabling our customers to accelerate their designs with new levels of power efficiency and performance through our rapidly growing hardware and software portfolio,” said Esam Elashmawi, Chief Strategy and Marketing Officer, Lattice Semiconductor. “We’re excited to expand on the strong customer and developer momentum we’ve established for Lattice Avant, enabling the next era of innovation.”

Innovative Mid-range FPGAs

Built on the award-winning Lattice Avant platform, the Avant-G and Avant-X FPGA families offer power efficiency, advanced connectivity, and optimized compute for mid-range applications across the Communications, Computing, Industrial, and Automotive markets.

Lattice Avant™-G FPGA Family
Avant-G general purpose FPGAs are designed to enable a wide range customer needs by offering seamless, flexible interface bridging and optimized compute for system expandability. Lattice Avant-G devices offer best-in-class signal processing and AI, flexible I/O supporting a range of system interfaces, while providing dedicated LPDDR4 memory interfaces at 2400 Mbps.

Lattice Avant™-X FPGA Family
Avant-X advanced connectivity FPGAs are designed to enable high bandwidth and security, with a feature set tailored to customer needs for signal aggregation and high throughput. Lattice Avant-X devices offer up to 1 Terabit per second total system bandwidth, PCIe® Gen 4 controllers with hard DMA, and a security engine to encrypt user data in motion providing quantum safe cryptography.

Lattice Avant-G and Avant-X FPGAs are sampling today and are supported by the latest releases of Lattice Propel™ and Lattice Radiant™ design software.

Expanded Solution Stacks

Lattice’s solution stacks are designed to speed customer development and time-to-market by giving them a toolkit of hardware, software, and IP tailored to the needs of their application. Lattice today announced four solution stack updates in AI with Lattice sensAI™, embedded vision with Lattice mVision™, security with Lattice Sentry™, and factory automation with Lattice Automate™. These updates include improved performance with upgraded an accelerator engine, expanded IP and reference designs, added security features, and enablement of more industry standards.

Enhanced Software Capabilities

Lattice is committed to providing best-in-class, easy-to-use software tools that help enhance customers’ design experience and design environment. Key updates to Lattice Propel™ and Lattice Radiant™ software includes adding full support for the new Lattice Avant-G and Avant-X FPGA families, the introduction of enhanced ease-of-use and scripting to Radiant, and expanding the IP portfolio in Propel.

Advanced computer vision software Glance by Mirametrix® was also updated with new features to expand its applicability across Edge applications for various markets. Updates include a new smart avatar privacy feature and 3D head pose for low power capability.

These product announcements were made today during the livecast at the Lattice Developers Conference, a replay of which will soon be available on the event portal site. Lattice Developers Conference is taking place virtually Dec. 5-7, 2023, featuring an incredible lineup of keynotes, breakout sessions, and a robust showcase of FPGA-based technology demonstrations from Lattice and other industry leaders.

For more information on the new products, please read the latest blog and visit:

About Lattice Semiconductor

Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.

For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, or Weibo.

Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.

GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MEDIA CONTACT:
Sophia Hong
Lattice Semiconductor
503-268-8786
Sophia.Hong@latticesemi.com

INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye